Cargando…

Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment

Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for more than 250 million cases of chronic liver infection, a condition that can lead to liver inflammation, cirrhosis, and hepatocellular carcinoma. Sodium taurocholate co-transporting polypeptide (NTCP), a transmembrane pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhou, Jun, Li, Tianliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039015/
https://www.ncbi.nlm.nih.gov/pubmed/35495620
http://dx.doi.org/10.3389/fmolb.2022.879817
_version_ 1784694029511819264
author Li, Yan
Zhou, Jun
Li, Tianliang
author_facet Li, Yan
Zhou, Jun
Li, Tianliang
author_sort Li, Yan
collection PubMed
description Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for more than 250 million cases of chronic liver infection, a condition that can lead to liver inflammation, cirrhosis, and hepatocellular carcinoma. Sodium taurocholate co-transporting polypeptide (NTCP), a transmembrane protein highly expressed in human hepatocytes and a mediator of bile acid transport, has been identified as the receptor responsible for the cellular entry of both HBV and its satellite, hepatitis delta virus (HDV). This has led to significant advances in our understanding of the HBV life cycle, especially the early steps of infection. HepG2-NTCP cells and human NTCP-expressing transgenic mice have been employed as the primary cell culture and animal models, respectively, for the study of HBV, and represent valuable approaches for investigating its basic biology and developing treatments for infection. However, the mechanisms involved in the regulation of NTCP transcription, translation, post-translational modification, and transport are still largely elusive. Improvements in our understanding of NTCP biology would likely facilitate the design of new therapeutic drugs for the prevention of the de novo infection of naïve hepatocytes. In this review, we provide critical findings regarding NTCP biology and discuss important questions that remain unanswered.
format Online
Article
Text
id pubmed-9039015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90390152022-04-27 Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment Li, Yan Zhou, Jun Li, Tianliang Front Mol Biosci Molecular Biosciences Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for more than 250 million cases of chronic liver infection, a condition that can lead to liver inflammation, cirrhosis, and hepatocellular carcinoma. Sodium taurocholate co-transporting polypeptide (NTCP), a transmembrane protein highly expressed in human hepatocytes and a mediator of bile acid transport, has been identified as the receptor responsible for the cellular entry of both HBV and its satellite, hepatitis delta virus (HDV). This has led to significant advances in our understanding of the HBV life cycle, especially the early steps of infection. HepG2-NTCP cells and human NTCP-expressing transgenic mice have been employed as the primary cell culture and animal models, respectively, for the study of HBV, and represent valuable approaches for investigating its basic biology and developing treatments for infection. However, the mechanisms involved in the regulation of NTCP transcription, translation, post-translational modification, and transport are still largely elusive. Improvements in our understanding of NTCP biology would likely facilitate the design of new therapeutic drugs for the prevention of the de novo infection of naïve hepatocytes. In this review, we provide critical findings regarding NTCP biology and discuss important questions that remain unanswered. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9039015/ /pubmed/35495620 http://dx.doi.org/10.3389/fmolb.2022.879817 Text en Copyright © 2022 Li, Zhou and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Li, Yan
Zhou, Jun
Li, Tianliang
Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title_full Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title_fullStr Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title_full_unstemmed Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title_short Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
title_sort regulation of the hbv entry receptor ntcp and its potential in hepatitis b treatment
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039015/
https://www.ncbi.nlm.nih.gov/pubmed/35495620
http://dx.doi.org/10.3389/fmolb.2022.879817
work_keys_str_mv AT liyan regulationofthehbventryreceptorntcpanditspotentialinhepatitisbtreatment
AT zhoujun regulationofthehbventryreceptorntcpanditspotentialinhepatitisbtreatment
AT litianliang regulationofthehbventryreceptorntcpanditspotentialinhepatitisbtreatment